CytomX Therapeutics Inc. | Income Statement
Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
888.00
5,077.00
7,712.00
15,043.00
71,623.00
59,502
SG&A Expense
15,189.00
34,059.00
39,709.00
72,896.00
116,237.00
135,492
EBIT
14,956.00
29,765.00
33,203.00
59,586.00
46,259.00
77,874
Unusual Expense
-
-
1,716.00
-
-
-
Non Operating Income/Expense
71.00
55.00
28.00
69.00
27.00
68
Interest Expense
254.00
487.00
1,732.00
1,689.00
-
-
Pretax Income
15,133.00
30,300.00
35,364.00
58,919.00
43,612.00
70,301
Income Tax
10.00
10.00
10.00
19.00
513.00
14,303
Consolidated Net Income
15,143.00
30,310.00
35,374.00
58,900.00
43,099.00
84,604
Net Income
15,143.00
30,310.00
35,374.00
58,900.00
43,099.00
84,604
Net Income After Extraordinaries
15,143.00
30,310.00
35,374.00
58,900.00
43,099.00
84,604
Net Income Available to Common
18,894.00
34,876.00
42,079.00
58,900.00
43,099.00
84,604
EPS (Basic)
0.53
0.97
4.90
1.63
1.16
2.03
Basic Shares Outstanding
35,920.60
35,920.60
8,595.20
36,234.70
37,166.80
41,664.40
EPS (Diluted)
0.53
0.97
4.90
1.63
1.16
2.03
Diluted Shares Outstanding
35,920.60
35,920.60
8,595.20
36,234.70
37,166.80
41,664.40
EBITDA
14,301.00
28,982.00
31,997.00
57,853.00
44,614.00
75,990
Non-Operating Interest Income
6.00
7.00
1,315.00
2,425.00
2,674.00
7,641
Preferred Dividends
3,751.00
4,566.00
6,705.00
-
-
-
About CytomX Therapeutics
View Profile
